431 related articles for article (PubMed ID: 17032350)
1. Brain site-specific gene expression analysis in Alzheimer's disease patients.
Yokota T; Mishra M; Akatsu H; Tani Y; Miyauchi T; Yamamoto T; Kosaka K; Nagai Y; Sawada T; Heese K
Eur J Clin Invest; 2006 Nov; 36(11):820-30. PubMed ID: 17032350
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the novel protein P9TLDR (temporal lobe down-regulated) with a brain-site-specific gene expression modality in Alzheimer's disease brain.
Yokota T; Akatsu H; Miyauchi T; Heese K
FEBS Lett; 2012 Dec; 586(24):4357-61. PubMed ID: 23159938
[TBL] [Abstract][Full Text] [Related]
3. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
van de Nes JA; Nafe R; Schlote W
Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease.
Wu ZL; Ciallella JR; Flood DG; O'Kane TM; Bozyczko-Coyne D; Savage MJ
Neurobiol Aging; 2006 Mar; 27(3):377-86. PubMed ID: 15927307
[TBL] [Abstract][Full Text] [Related]
5. Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis.
Suzuki T; Araki Y; Yamamoto T; Nakaya T
J Biochem; 2006 Jun; 139(6):949-55. PubMed ID: 16788045
[TBL] [Abstract][Full Text] [Related]
6. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains.
Wilhelmus MM; Otte-Höller I; Wesseling P; de Waal RM; Boelens WC; Verbeek MM
Neuropathol Appl Neurobiol; 2006 Apr; 32(2):119-30. PubMed ID: 16599941
[TBL] [Abstract][Full Text] [Related]
7. LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease.
Majercak J; Ray WJ; Espeseth A; Simon A; Shi XP; Wolffe C; Getty K; Marine S; Stec E; Ferrer M; Strulovici B; Bartz S; Gates A; Xu M; Huang Q; Ma L; Shughrue P; Burchard J; Colussi D; Pietrak B; Kahana J; Beher D; Rosahl T; Shearman M; Hazuda D; Sachs AB; Koblan KS; Seabrook GR; Stone DJ
Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17967-72. PubMed ID: 17098871
[TBL] [Abstract][Full Text] [Related]
8. Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease.
Rensink AA; Gellekink H; Otte-Höller I; ten Donkelaar HJ; de Waal RM; Verbeek MM; Kremer B
Acta Neuropathol; 2002 Nov; 104(5):525-33. PubMed ID: 12410400
[TBL] [Abstract][Full Text] [Related]
9. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ
Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910
[TBL] [Abstract][Full Text] [Related]
10. Beta-amyloid controls altered Reelin expression and processing in Alzheimer's disease.
Botella-López A; Cuchillo-Ibáñez I; Cotrufo T; Mok SS; Li QX; Barquero MS; Dierssen M; Soriano E; Sáez-Valero J
Neurobiol Dis; 2010 Mar; 37(3):682-91. PubMed ID: 20025970
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of muscarinic acetylcholine receptor M2 adversely affects the expression of Alzheimer's disease-relevant genes and proteins.
Zuchner T; Schliebs R; Perez-Polo JR
J Neurochem; 2005 Oct; 95(1):20-32. PubMed ID: 16181410
[TBL] [Abstract][Full Text] [Related]
12. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
[TBL] [Abstract][Full Text] [Related]
13. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison.
Jeynes B; Provias J
Acta Neuropathol; 2006 Oct; 112(4):417-27. PubMed ID: 16830133
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease pathogenesis and therapeutic interventions.
Parihar MS; Hemnani T
J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
[TBL] [Abstract][Full Text] [Related]
15. beta-Amyloid, protein processing and Alzheimer's disease.
Haas C; Hung AY; Citron M; Teplow DB; Selkoe DJ
Arzneimittelforschung; 1995 Mar; 45(3A):398-402. PubMed ID: 7763333
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
17. The expression of calcium/calmodulin-dependent protein kinase II-alpha in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology.
Wang YJ; Chen GH; Hu XY; Lu YP; Zhou JN; Liu RY
Brain Res; 2005 Jan; 1031(1):101-8. PubMed ID: 15621017
[TBL] [Abstract][Full Text] [Related]
18. Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains.
Zhou XW; Li X; Bjorkdahl C; Sjogren MJ; Alafuzoff I; Soininen H; Grundke-Iqbal I; Iqbal K; Winblad B; Pei JJ
Neurobiol Dis; 2006 Jun; 22(3):657-68. PubMed ID: 16513361
[TBL] [Abstract][Full Text] [Related]
19. Abundant expression of zinc transporters in the amyloid plaques of Alzheimer's disease brain.
Zhang LH; Wang X; Stoltenberg M; Danscher G; Huang L; Wang ZY
Brain Res Bull; 2008 Sep; 77(1):55-60. PubMed ID: 18639746
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner.
Thal DR; Capetillo-Zarate E; Schultz C; Rüb U; Saido TC; Yamaguchi H; Haass C; Griffin WS; Del Tredici K; Braak H; Ghebremedhin E
Acta Neuropathol; 2005 Nov; 110(5):459-71. PubMed ID: 16195918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
